Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bolis

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1985
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trialC Sessa, G Bolis, N Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Ovarian cancer risk and history of selected medical conditions linked with female hormonesF Parazzini, S Moroni, C La Vecchia, et al.
Gynecologic Oncology|November 1, 1990
The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapyG Bolis, F Zanaboni, P Vanoli, et al.
Gynecologic Oncology|November 1, 1988
EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)G Bolis, C Bonazzi, F Landoni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1980
Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical studyG Bolis, G Bortolozzi, G Carinelli, et al.
European Journal of Cancer|January 1, 1979
Decreased half life of cyclophosphamide in patients under continual treatmentM D'Incalci, G Bolis, T Facchinetti, et al.
Gynecologic Oncology|July 1, 1999
Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survivalF Parazzini, G Valsecchi, G Bolis, et al.
European Journal of Gynaecological Oncology|January 19, 2013
Ten years survival of FIGO stage IIIC epithelial ovarian cancer cases due to lymph node metastases onlyE Grossi, S Noli, G Scarfone, et al.
Tumori|February 29, 1988
Analysis of 309 cases after hydatidiform mole: different follow-up program according to biologic behaviorG Bolis, C Belloni, C Bonazzi, et al.
Tumori|June 30, 1987
Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumorG Bolis, N Colombo, A Epis, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|January 1, 1985
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trialC Sessa, G Bolis, N Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Ovarian cancer risk and history of selected medical conditions linked with female hormonesF Parazzini, S Moroni, C La Vecchia, et al.
Gynecologic Oncology|November 1, 1990
The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapyG Bolis, F Zanaboni, P Vanoli, et al.
Gynecologic Oncology|November 1, 1988
EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)G Bolis, C Bonazzi, F Landoni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1980
Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical studyG Bolis, G Bortolozzi, G Carinelli, et al.
European Journal of Cancer|January 1, 1979
Decreased half life of cyclophosphamide in patients under continual treatmentM D'Incalci, G Bolis, T Facchinetti, et al.
Gynecologic Oncology|July 1, 1999
Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survivalF Parazzini, G Valsecchi, G Bolis, et al.
European Journal of Gynaecological Oncology|January 19, 2013
Ten years survival of FIGO stage IIIC epithelial ovarian cancer cases due to lymph node metastases onlyE Grossi, S Noli, G Scarfone, et al.
Tumori|February 29, 1988
Analysis of 309 cases after hydatidiform mole: different follow-up program according to biologic behaviorG Bolis, C Belloni, C Bonazzi, et al.
Tumori|June 30, 1987
Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumorG Bolis, N Colombo, A Epis, et al.
Pageof 13